Trial reportJAMA network open2025
Eppikajutsuto for Treatment of Lymphatic Malformations in Children: A Nonrandomized Clinical Trial.
Trial report in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Duagnosis: Locating Clinical Uncertainty in the Diagnostic Framework.Journal of evaluation in clinical practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Lymphatic malformations (LMs) are congenital vascular anomalies with limited treatment options. Eppikajutsuto, a traditional Japanese (Kampo) herbal medicine, is commonly used to treat inflammatory conditions and has been reported to reduce lesion volume in patients with LMs; however, data on its effectiveness in pediatric patients are needed. Objective: To evaluate the association of eppikajutsuto with reduced LM lesion volume in pediatric patients with LMs. Design, Setting, and Participants: This open-label nonrandomized clinical trial was conducted from April 14, 2021, to September 30, 2024, at multiple centers in Japan. Eligible participants were 18 years or younger with a confirmed diagnosis of LM by imaging. Data were analyzed from October 14, 2024, to March 4, 2025. Intervention: Participants received eppikajutsuto granules (0.6 g/kg/d to ≤7.5 g/d) orally for 6 months. Main Outcomes and Measures: The primary outcome was the proportion of patients achieving a 20% or greater reduction in lesion volume, measured with magnetic resonance imaging volumetry at baseline and 6 months. Secondary outcomes included a 50% or greater reduction in lesion volume, median shrinkage rate, improvement in quality of life, and safety. Results: A total of 19 patients (10 male [52.6%]; mean [SD] age, 24.1 [29.4] months) were enrolled. A total of 10 patients (52.6%; 90% CI, 32.0%-73.0%) achieved a 20% or greater reduction in lesion volume at 6 months. The median shrinkage rate was 22.9% (IQR, -142.3% to 96.0%). No serious adverse events occurred, and medication adherence of 70% or greater was observed in 17 of 19 patients (89.5%). Conclusions and Relevance: In this nonrandomized clinical trial of children with LMs, eppikajutsuto was associated with a reduction in lesion volume and was well tolerated. Further studies, including randomized clinical trials, are warranted to confirm these findings. Trial Registration: Japan Registry of Clinical Trials Identifier: jRCTs041210007.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.